<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842163</url>
  </required_header>
  <id_info>
    <org_study_id>B3461058</org_study_id>
    <secondary_id>TTRACK</secondary_id>
    <nct_id>NCT03842163</nct_id>
  </id_info>
  <brief_title>Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology</brief_title>
  <acronym>TTRACK</acronym>
  <official_title>PREVALENCE AND CHARACTERISTICS OF TRANSTHYRETIN AMYLOIDOSIS IN PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY OF UNKNOWN ETIOLOGY TTRACK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the prevalence of ATTR Cardiomyopathy among
      patients admitted due to Left Ventricular Hypertrophy (LVH) &gt;15mm of unknown etiology by
      using a 99mTc-tracer scintigraphy based protocol
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with cardiac fixation at the radionuclide bone scintigraphy</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>To assess the prevalence of patients with cardiac fixation at the radionuclide bone scintigraphy performed with 99mTc-DPD or 99mTc-PYP or 99mTc-HMDP among patients with HCM from undiagnosed etiology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with mutation at (Transthyretin) TTR coding gene</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>To assess the prevalence of hereditary (TTRm) or senile (TTRwt) A-TTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with familial history</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>To assess the prevalence of patients with familial history of known cardiomyopathy (CM), polyneuropathy (PN), sudden cardiac death (SCD) among their relatives (parents, siblings and 2nd /3rd grade family)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with concomitant signs and symptoms of ATTR amyloidosis</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>To assess the prevalence of patients with cardiac fixation at the bone scintigraphy of patients with concomitant signs or symptoms of A-TTR, i.e.:
Senso-motor Polyneuropathy
Carpal Tunnel syndrome (CTS)
Autonomic dysfunction
Cardiological manifestations
Laboratory signs
Others</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of neurogical signs and/or symptoms compatible with ATTR Polyneuropathy</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>To assess the coexistence of typical neurological signs/symptoms even when overlooked at the first evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of specific TTR gene mutation if present</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>To describe the prevalence of TTR genetic mutation** in patients with cardiac fixation at the bone scintigraphy ( visual grade 1 to 3)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)</condition>
  <arm_group>
    <arm_group_label>Patients with LVH of unknown etiology</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnosis of TTR amyloidosis cardiomyopathy</intervention_name>
    <description>Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy</description>
    <arm_group_label>Patients with LVH of unknown etiology</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HCM from undiagnosed etiology
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age ≥ 50 years

          -  Left ventricular hypertrophy (LVH): (Defined by end-diastolic LV maximum wall
             thickness (MWT) ≥15mm in ECHO)

        Exclusion criteria:

          -  Etiological diagnosis explaining the LVH:

             o Sarcomeric HCM, Myeloma, Fabry disease, Sarcoidosis, Any type of amyloidosis (AA,
             AL, TTR*...)

          -  Severe aortic stenosis (Aortic valve area (AVA) &lt; 1.0 cm2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck - Universitätsklinik für Innere Medizin III, Kardiologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Caen</name>
      <address>
        <city>Caen</city>
        <state>Cedex</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Divisione di Cardiologia</name>
      <address>
        <city>Bologna</city>
        <zip>40128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Careggi Hospital</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inherited Cardiovascular Diseases - Cardiology Institute</name>
      <address>
        <city>Bucharest</city>
        <zip>030171</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana - Department of Cardiology</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario A Coruna</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Italy</country>
    <country>Romania</country>
    <country>Slovenia</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B3461058</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scintigraphy</keyword>
  <keyword>Gammagraphy</keyword>
  <keyword>TTR</keyword>
  <keyword>ATTR</keyword>
  <keyword>Hipertrophic cardiomyopathy (HCM)</keyword>
  <keyword>HCM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloid Neuropathies, Familial</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

